Close Menu

Mirus

Mirus Bio has introduced the TransIT-X2 dynamic delivery system.
According to the company, the polymeric nucleic acid-delivery system can be used for independent or simultaneous delivery of DNA and siRNA to a variety of cell types.

Arrowhead Research's top executive this week broke out details on the company's efforts to move its RNAi-based hepatitis B virus treatment ARC-520 into the clinic, stating that the firm will run two phase I trials in order to speed up the generation of key human data.

Arrowhead Research last week released new preclinical data on its lead drug candidate, the hepatitis B virus treatment ARC-520, reporting that the agent could trigger up to multi-log reductions in the levels of circulating viral antigens, while lowering levels of the virus' repli

Arrowhead Research announced this week that it has signed a RNAi services agreement with Germany's Axolabs, bringing together the US and European halves of Roche's former RNA therapeutics operations that were divested by the biopharmaceutical giant in 2010.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.